Pharmacyte Biotech Inc (PMCB)

May 21, 2024, 9:00 AM EDT - 11 months ago

MyMD Pharmaceuticals Secures Strategic Investments

May 21, 2024, 9:00 AM EDT - 11 months ago

PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease

Nov 15, 2023, 8:30 AM EST - 1 year ago

PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.

FEMY

Oct 31, 2023, 9:15 AM EDT - 1 year ago

PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology

Jun 15, 2023, 9:15 AM EDT - 2 years ago

PharmaCyte Biotech Announces Final Results of Tender Offer

May 11, 2023, 8:30 AM EDT - 2 years ago

PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share

Feb 2, 2023, 9:00 AM EST - 2 years ago

PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan

Oct 7, 2022, 9:00 AM EDT - 2 years ago

PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value

Aug 15, 2022, 8:30 AM EDT - 2 years ago

PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital

Jul 28, 2022, 12:49 PM EDT - 2 years ago

PharmaCyte Biotech Rebukes Iroquois' Commencement of Consent Solicitation

Jul 28, 2022, 9:00 AM EDT - 2 years ago

Iroquois Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech, Inc.

Jul 21, 2022, 8:30 AM EDT - 2 years ago

PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study

Jul 19, 2022, 8:30 AM EDT - 2 years ago

PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study

Jul 11, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022

Jul 11, 2022, 6:00 AM EDT - 3 years ago

IROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORS

Jul 5, 2022, 3:16 PM EDT - 3 years ago

IROQUOIS CAPITAL ISSUES STATEMENT IN RESPONSE TO RECENT ACTIONS BY THE PHARMACYTE BIOTECH BOARD OF DIRECTORS

Jul 5, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells

Jun 23, 2022, 9:00 AM EDT - 3 years ago

IROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETING

Jun 15, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital's Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value

Jun 13, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego

Jun 9, 2022, 9:00 AM EDT - 3 years ago

IROQUOIS CAPITAL DELIVERS OPEN LETTER TO PHARMACYTE BIOTECH BOARD OF DIRECTORS

Jun 8, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value

Jun 2, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech to Implement $10-Million Share Repurchase Program

May 23, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites

May 11, 2022, 9:00 AM EDT - 3 years ago

Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors

Apr 27, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes

Apr 19, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements

Apr 13, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial

Apr 5, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors

Mar 22, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate

Mar 16, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights

Feb 22, 2022, 9:00 AM EST - 3 years ago

PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration

Feb 14, 2022, 9:00 AM EST - 3 years ago

PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA

Jan 7, 2022, 2:59 AM EST - 3 years ago

Is This A Good Time To Invest In PharmaCyte?

Jan 6, 2022, 9:00 AM EST - 3 years ago

PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference

Jan 4, 2022, 9:00 AM EST - 3 years ago

PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells

Dec 28, 2021, 9:00 AM EST - 3 years ago

PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study

Dec 15, 2021, 9:00 AM EST - 3 years ago

PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights

Dec 8, 2021, 10:16 AM EST - 3 years ago

PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay

Nov 30, 2021, 1:05 AM EST - 3 years ago

PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study

Nov 12, 2021, 9:00 AM EST - 3 years ago

PharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin Irritation

Sep 27, 2021, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNA

Sep 21, 2021, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility Tests

Sep 16, 2021, 1:51 PM EDT - 3 years ago

Why Are PharmaCyte Shares Moving Higher On Thursday?

Sep 16, 2021, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDA

Sep 9, 2021, 8:57 AM EDT - 3 years ago

Why Is PharmaCyte Biotech Stock Moving Higher In Premarket Thursday?

Sep 8, 2021, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

Aug 31, 2021, 9:20 AM EDT - 3 years ago

PharmaCyte Biotech Establishes 18-Month Shelf Life for Clinical Trial Product in Ongoing Stability Study

Aug 25, 2021, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise

Aug 23, 2021, 4:39 PM EDT - 3 years ago

PharmaCyte Biotech Announces Closing of $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules